Sign in
Not yet taking people in United StatesNo phase

Lithium Dosing Study

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Status
Not yet recruiting
People taking part
250 people, planned
Started
16 Nov 2026
Expected to end
1 Nov 2027
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lithium Orotate (LiO)
  • Placebo
Record updated
16 November 2026

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Age 60 years or older at study entry Self-reported ability to read and understand English. As all study surveys have been validated in English, we will limit participation to potential subjects able to read English
  • Able to provide informed consent
  • Must meet criteria for one of the three following cognitive statuses:
  • Cognitively normal/unimpaired, (TICS-41 score ≥34 with presence of subjective cognitive concerns and without significant hearing impairment
  • For those without hearing impairment, TICS-41 score 23 to <34 (mild objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of MCI
  • For those without hearing impairment, TICS-41 score >15 to <23 (moderate objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of mild-stage AD dementia
  • Must be able and willing to adhere to study procedures
  • Participants with moderate objective impairment or clinician diagnosis of AD dementia must have a study partner willing to participate in the study with them

Who cannot take part

  • Concurrent use of anti-amyloid therapies (e.g., Donanemab, Lecanemab)
  • Concurrent participant in an ongoing clinical trial involving taking a study drug or supplement
  • History of lithium toxicity, intolerance or hypersensitivity
  • History of diagnosed kidney disorders (e.g., chronic kidney disease, dialysis or renal transplant, acute kidney injury within past 6 months)
  • Unstable thyroid disorders (e.g., medication change in the last 90 days) or history of thyroid surgery, radioactive iodine treatment or active thyroiditis in the last 90 days
  • Self-reported major psychiatric and neurological disorders
  • Bipolar disorder, schizophrenia, or unstable major depression (e.g., recent hospitalization, medication change in the last 90 days)
  • To optimize participant safety and to ensure that individuals with any degree of suicidal ideation at baseline are not included in the study, the presence of any suicidal ideation at screening will be defined as a score of >0 on PHQ-9 Item 9 or as spontaneously reported during screening. The PHQ-9 will also be administered at 6- and 12-week follow-up time points as a safety monitoring measure. A score of 1 or greater on PHQ-9 Item 9, or spontaneous report of current suicidal ideation at any point during the study, will trigger the suicidality and psychiatric safety procedures detailed under 'Monitoring and Quality Assurance'
  • Parkinson disease or other non-AD neurodegenerative disorders (e.g., Huntington's disease)
  • Self-reported medical conditions
  • Diagnosis of cardiovascular disease or major cardiovascular procedures in the last 6 months (e.g., cardiac conduction abnormalities, heart attack, stroke, transient ischemic attack, angina pectoris, coronary-artery bypass grafting, percutaneous coronary intervention, cardioversion or ablation)
  • Diagnosis or treatment of cancer (except non-melanoma skin cancer) in the last 6 months
  • History of liver disease
  • Score of >50% likelihood of significant hearing impairment according to the Hearing Handicap Inventory-Screening Version (HHIE-S)
  • Any other serious illness or condition that, in the opinion of the investigators, would preclude safe participation or completion of the study procedures
  • Those with hearing impairment who do not report a clinician diagnosis of MCI or AD dementia given concerns for lack of awareness of objective memory decline which could lead to incorrect categorization without use of the TICS-41
  • Failure to complete the baseline blood collection
  • Lab values within the abnormal range (adjusted for age and sex where relevant) for renal function, reflex thyroid tests, and liver function
  • Lithium-specific exclusions
  • Use of any lithium formulation in the last six months
  • Unwilling to forego use of any non-study lithium formulation during the trial
  • Other exclusions
  • TICS-41 score ≤15
  • Those who report "severe" for items 21-29 on the LiSERS questionnaire
  • UBACC (the University of California, San Diego Brief Assessment of Capacity to Consent) < 11 indicating inability to provide informed consent. The clinical research coordinator will conduct a comprehension check of the consent form using the UBACC, which will require a perfect score of 11 out of 11 points to indicate capacity to provide informed consent. Prospective participants will be allowed two tries of the UBACC to achieve a score of 11
  • Must reside in the states of Connecticut, Rhode Island, Massachusetts, Maine, New Hampshire, or Vermont and be able to have blood draws completed at a New England Quest location in those states

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: Olivia I Okereke, MDNot yet recruiting

About the trial

What the trial wants to find out

LiDS is a dosing study to evaluate the safety, tolerability, and feasibility of daily oral Lithium Orotate (LiO) in aging adults at increased risk for progression of cognitive problems, including Alzheimer's disease and related dementias.

The 5 groups in the trial

  • PlaceboPlacebo, for comparison

    Placebo pill taken daily for the 12 week study participation period. Placebo pills are in packaging identical to the LiO groups.

  • 0.5 mg/dayExisting treatment, for comparison

    0.5 mg/day of LiO pills for the 12 week study participation period.

    Treatment: Lithium Orotate (LiO)

  • 1.0 mg/dayExisting treatment, for comparison

    1.0 mg/day of LiO pills for the 12 week study participation period.

    Treatment: Lithium Orotate (LiO)

  • 2.5 mg/dayExisting treatment, for comparison

    2.5 mg/day of LiO pills for the 12 week study participation period.

    Treatment: Lithium Orotate (LiO)

  • 5.0 mg/dayExisting treatment, for comparison

    5.0 mg/day of LiO pills for the 12 week study participation period.

    Treatment: Lithium Orotate (LiO)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dosing Study of Lithium Orotate for Safety, Tolerability, and Feasibility for Early Stages of Alzheimer's Disease and Related Dementias
Record updated
16 November 2026